BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 38625698)

  • 1. Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Banna GL; Hassan MA; Signori A; Giunta EF; Maniam A; Anpalakhan S; Acharige S; Ghose A; Addeo A
    JAMA Netw Open; 2024 Apr; 7(4):e246837. PubMed ID: 38625698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
    Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
    JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
    Nuccio A; Viscardi G; Salomone F; Servetto A; Venanzi FM; Riva ST; Oresti S; Ogliari FR; Viganò M; Bulotta A; Cameron R; Esposito A; Hines J; Bianco R; Reni M; Cascone T; Garassino MC; Torri V; Veronesi G; Cinquini M; Ferrara R
    Eur J Cancer; 2023 Dec; 195():113404. PubMed ID: 37948842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.
    Zhang SL; Tian Y; Yu J; Zhang JH; Sun L; Huang LT; Ma JT; Han CB
    Lung Cancer; 2024 May; 191():107799. PubMed ID: 38669725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
    Front Immunol; 2021; 12():731546. PubMed ID: 34484242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Takahashi M; Cortés J; Dent R; Pusztai L; McArthur H; Kümmel S; Denkert C; Park YH; Im SA; Ahn JH; Mukai H; Huang CS; Chen SC; Kim MH; Jia L; Li XT; Tryfonidis K; Karantza V; Iwata H; Schmid P
    JAMA Netw Open; 2023 Nov; 6(11):e2342107. PubMed ID: 37966841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis.
    Wu Y; Hu L; Zhang S; Zhang H
    Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
    Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
    Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
    J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
    Xin Y; Shen G; Zheng Y; Guan Y; Huo X; Li J; Ren D; Zhao F; Liu Z; Li Z; Zhao J
    BMC Cancer; 2021 Nov; 21(1):1261. PubMed ID: 34814874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
    Zhu J; Yuan Y; Wan X; Yin D; Li R; Chen W; Suo C; Song H
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD011300. PubMed ID: 34870327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
    Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
    Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY
    Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.
    Zhang X; Zhang H; Hou F; Fang T; Zhang C; Wang H; Song S; Lan H; Wang Y; Hou H
    World J Surg Oncol; 2024 Jun; 22(1):159. PubMed ID: 38890622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Maiorano BA; Di Maio M; Cerbone L; Maiello E; Procopio G; Roviello G;
    JAMA Netw Open; 2024 Mar; 7(3):e241215. PubMed ID: 38446479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
    Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.